In HER2-positive BC, the upregulation of Gi/o-GPCRs stimulate HER2 transactivation and drive activation of effectors shared by Gi/o-GPCRs and EGFR/HER2, such as AKT and Src, promoting tumor growth and metastasis. Here, ERBB2 is linked to breast cancer.